How Pharma Buyers Actually Decide Which CDMO Wins
By Matthew Holt, Co-Founder, Collaborative Sourcing
Every CDMO (Contract Development and Manufacturing Organisation) pitch deck looks roughly the same. Modern facilities. Regulatory track record. Flexible capacity. A slide about "partnership." If you've sat through a handful of these, as I have, you start to notice that the differentiation everyone claims rarely shows up in the decision.
So what actually decides it?
The RFP Is Not the Real Evaluation
Most CDMO selection processes are built around a Request for Proposal (RFP): a scored matrix of capability, capacity, quality metrics, and price. It's necessary — but it's not where the decision actually gets made. In my experience running and advising on these processes, the RFP filters out who's unqualified. It rarely tells you who's right.
The real evaluation happens in three places the scorecard doesn't capture well:
How they handle the first problem. Every relationship hits friction — a delayed batch, a spec query, a capacity clash. I pay close attention to how a prospective CDMO handles a small issue during the evaluation process itself, before any contract exists. If they're defensive or slow when there's nothing at stake yet, that's the relationship you're signing up for at scale.
Who you're actually talking to. A confident business development lead can make any facility sound exceptional. The people who matter are the ones you'll deal with after signature — the project manager, the quality lead, the person who picks up the phone when a batch is delayed. If you haven't met them before you sign, you're evaluating the wrong team.
Whether capacity claims survive a direct question. "We have capacity" is the most common phrase in a CDMO pitch and the least reliable. Ask when that capacity is actually free, not theoretically available. Ask what else is competing for it. The answer tells you more than the number on the slide.
Why This Matters More Than It Used To
Post-pandemic supply chain disruption and the current push toward reshoring and dual sourcing (bringing manufacturing closer to home, or deliberately using more than one supplier for a critical input) have made CDMO selection a board-level conversation, not just a procurement exercise. A UK Government Office for Science review of supply chain risk earlier this year highlighted exactly this shift: visibility gaps and risk concentration are increasingly happening not at the finished product tier, but one or two tiers up — precisely where CDMO responsibilities sit. Getting this decision wrong doesn't just cost money; it costs time you often don't have, particularly for time-sensitive clinical or launch programmes.
A Simple Filter: Trust vs Transparency
The framework I come back to with clients is deceptively simple: plot a prospective CDMO on two axes — trust (do they do what they say, consistently, over time) and transparency (do they tell you the truth even when it's inconvenient, like a delay or a capacity constraint).
Most CDMOs can demonstrate trust reasonably well during a sales process — references, certifications, site visits. Transparency is harder to fake and far more predictive. A supplier who tells you about a problem before you ask is fundamentally different from one who tells you only when you catch it. The second relationship will cost you more than price ever will.
A Real Example
On a recent engagement, a client had shortlisted two CDMOs almost identical on paper — similar certifications, comparable pricing, both with available capacity in the right window. The deciding factor wasn't in either proposal. During reference calls, one CDMO's existing client mentioned, unprompted, a batch delay from eighteen months earlier — and specifically how early they'd been told about it, and how the CDMO had proactively adjusted the schedule. That single data point carried more weight than every slide in either deck.
The Question to Ask Yourself
Before your next CDMO selection, it's worth asking: is our evaluation process actually designed to surface trust and transparency, or is it designed to produce a defensible scorecard? Those aren't always the same thing, and the gap between them is where expensive mistakes tend to live.
Matthew Holt is Co-Founder of Collaborative Sourcing, a procurement consultancy for pharmaceutical, life sciences, and CDMO sectors. His background is in API sourcing and CMO/CDMO management, helping clients move from reactive firefighting to predictable, trust-based supply partnerships.